VA must stock new non-opioid pain drugs within a year
H.R. 4509 — NOPAIN for Veterans Act · Filed by Greg Landsman (D-OH) · 35 cosponsors · Introduced Jul 17, 2025 · Hearing held
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the VA to add newly approved non-opioid pain medications to its national formulary within one year of FDA approval, and to include them on the drug standardization list. It defines non-opioid pain drugs as FDA-approved medications that reduce post-operative or post-surgical pain without acting on opioid receptors. Veterans gain access to newer pain-management alternatives; the VA must implement the change within 90 days.
Why we flagged it
The bill is a straightforward mandate to expand VA access to non-opioid pain medications. It is a public-health measure aimed at improving veteran care and reducing opioid dependence, with no narrow private carve-outs or hidden riders.
What the text implies
- The bill ties VA formulary inclusion to Medicare/Medicaid payment determinations (Social Security Act § 1833(t)(16)(G) and CFR § 416.174), meaning VA adoption follows federal payment policy rather than independent clinical review—this may accelerate adoption of expensive new drugs if Medicare deems them separately payable.
- The one-year timeline for inclusion may create pressure on VA pharmacy systems to rapidly integrate new drugs, potentially straining implementation capacity or clinical vetting processes.
The full analysis lists 3 implications of this text.
Who stands to gain
pharmaceutical manufacturers of non-opioid pain medications; biotech companies developing post-operative pain alternatives